JP Morgan Chase’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

JP Morgan Chase’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$466	–	7461
2024 Q4	$466	Buy	+100	New	+$654	﹤0.01%	6810
2024 Q3	–	Sell	-118	Closed	-$1.41K	–	7509
2024 Q2	$1.41K	Hold	118	–	–	﹤0.01%	6569
2024 Q1	$2.31K	Buy	118 +84	+247%	+$1.49K	﹤0.01%	6558
2023 Q4	$611	Hold	34	–	–	﹤0.01%	6901
2023 Q3	$614	Hold	34	–	–	﹤0.01%	6697
2023 Q2	$2.15K	Hold	34	–	–	﹤0.01%	6324
2023 Q1	$2K	Hold	34	–	–	﹤0.01%	6417
2022 Q4	$1K	Hold	34	–	–	﹤0.01%	6408
2022 Q3	$2K	Hold	34	–	–	﹤0.01%	6250
2022 Q2	$1K	Sell	34 -37	-52%	-$1.7K	﹤0.01%	6353
2022 Q1	$4K	Buy	+71	New	+$3.99K	﹤0.01%	6349

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

JP Morgan Chase's DMRA Position: Q1 2025 in Review

JP Morgan Chase sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2025, closing a stake of 100 shares — an estimated $466 sold.

JP Morgan Chase first reported a position in DMRA in Q1 2022 and held it in 11 quarters. The position peaked at $4K in Q1 2022. 11 funds tracked by Wall St. Rank hold DMRA as of Q1 2025.

JP Morgan Chase reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 100 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2025, an estimated $466.
JP Morgan Chase first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q1 2022 and held it in 11 quarters.
JP Morgan Chase's Damora Therapeutics, Inc. Ordinary Shares position peaked at $4K in Q1 2022.
11 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.